Category Archives: Global News Feed

DURHAM, N.C., April 18, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (NYSE American: HTBX), a clinical-stage biopharmaceutical company focused on developing first-in-class therapies to modulate the immune system and novel biodefense assets, reminds investors that it will host an investor and media livestream event on Tuesday, April 19, 2022 at 10:30 AM Eastern Time to discuss the latest developments. The event will be broadcast at: https://vimeo.com/event/2027558/fc6de52c31

Go here to read the rest:
REMINDER: Heat Biologics to Host Planned Investor and Media Livestream Event on Tuesday, April 19th at 10:30 AM ET to Discuss Latest Developments

WESTMINSTER, Colo., April 18, 2022 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that its Board of Directors has established a Special Committee to evaluate strategic options for maximizing stockholder value.   The Company believes there are multiple potential opportunities to enhance value for ARCA stockholders. The Special Committee includes ARCA Board Chairman Robert E. Conway (chair), and Board members Linda Grais, M.D. and Anders Hove, M.D.

More here:
ARCA biopharma Establishes Special Committee of the Board of Directors

IRVINE, Calif., April 18, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that Steve Perrin, Ph.D., President and Chief Scientific Officer, will present at NobleCon18, Noble Capital Markets’ Eighteenth Annual Investor Conference on Thursday, April 21st at 11:30 a.m. ET.

Go here to see the original:
Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

PHILADELPHIA, April 18, 2022 (GLOBE NEWSWIRE) -- Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the management team will present at the virtual Chardan Genetic Medicines and Cell Therapy Manufacturing Summit on Monday, April 25, 2022, at 9:30 AM ET.

Follow this link:
Century Therapeutics to Present at the Chardan Genetic Medicines and Cell Therapy Manufacturing Summit

ST. LOUIS, April 19, 2022 (GLOBE NEWSWIRE) -- Curium announced today that it will be increasing production capacity of Detectnet to accommodate the significant demand in the market. Curium will now be offering 50% more doses for patient use Monday-Friday beginning the week of May 1, 2022.

The rest is here:
Curium Announces Significant Increase in Detectnet™ (copper Cu 64 dotatate injection) Production Capacity

COPENHAGEN, Denmark, April 5, 2022 – Bavarian Nordic A/S (OMX: BAVA) today held the Annual General Meeting with the following results:

The rest is here:
Resolutions of the Annual General Meeting 2022 of Bavarian Nordic A/S

MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

Link:
MoonLake Immunotherapeutics AG Announces Closing of Business Combination with Helix Acquisition Corp.

Shareholders of Infant Bacterial Therapeutics AB (publ) are summoned to the Annual General Meeting on Wednesday, May 4, 2022. In light of the coronavirus, the Annual General Meeting is conducted through advance voting pursuant to temporary regulations. Therefore, it will not be possible to attend this year’s Meeting in person or by proxy.

Read more here:
Notice to attend the Annual General Meeting of Infant Bacterial Therapeutics

Atreca Announces Licensing Agreement with Zymeworks

Read the original post:
Atreca Announces Expansion of Preclinical Pipeline

Positive FDA Feedback on Potency Assay Matrix to Support BLA Submission

Read more:
Iovance Biotherapeutics Announces Regulatory and Clinical Updates for Lifileucel in Melanoma